DKBmed Radio

In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221)

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/222/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/218)

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216)

The primary health concern for all individuals living with HIV should be managing their disease, particularly maintaining adherence to their ART treatment. Yet for many, the more immediate demands of their substance use disorder — whether for stimulants and/or opioids — take precedence and can readily become the central focus of their lives. What signals can help a clinician recognize a substance use disorder? How can they differentiate a clinical SUD from intermittent (even though harmful) substance use? What evidence-based treatments should they consider?Post-test for CME credits: https://elit.dkbmed.com/issues/217/test

CLAIM CME/CE CREDIT HERE: https://dkbmed.com/programs/209/sections/122/evaluationInfluenza remains a perennial public health threat, and urgent and convenient care providers serve an essential role in treating patients who become infected with the virus. This webinar will help you recognize patients at high risk of severe illness caused by the flu and determine when to use influenza antivirals. Importantly, you will also learn several strategies that can help you avoid inappropriate use of antibiotics. Watch now to enhance your flu season readiness and elevate the care you provide to your patients.Credit available: 1.0 of ANCC, AMA, or AAPA

Giving birth and raising a family. For many people with MS, the path to achieving those goals contains more questions than answers. Questions about timing — which should come first, pregnancy or disease stability on a DMT? Questions about genetics — can MS be passed on to the baby? Questions about fertility — is in vitro fertilization safe and effective, and how much does it increase disease activity? Questions their treating clinicians may not be able to answer with the most current research.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/215/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/214)